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ABSTRACT
BACKGROUND: Benincasa hispida Cogn. has been used traditionally in India for
the management of urinary disorders. The fruit of B hispida is used as a diuretic and
the seeds have been reported to possess antiangiogenic effccts in prostate cells.
OBJECTIVE: The aim of the present study was to examine the effect of petroleum
ether extract, ethanolic extract , and B hispida seed oil on hyperplasia of the prostate
induced by the subcutaneous administration of testosterone in rats.
METHODS: In vitro studies were performed to determine the Sa-reductase in-
hib itory potential of the extracts. The results of those stu d ies paved the way for th e
ph armacolog ic screen ing of the extracts to assess their potential against testosterone-
induced hyperplasia in rats. N ine groups contai ning 10 rats per g roup were created
for this stu dy. H yperplasia was indu ced by administration of testosterone (3 mg/kg
SC) for 14 days in all th e g roups except the vehicle-treated g roup. Simultaneous
administrat ion of petroleum eth er extr act (loa or 200 rng/kg PO), ethanolic extract
(100 or 200 mg/kg PO ), and B hispida seed oil (20 or 40 mg/kg PO ) was conducted .
A standard Sa-reductase inh ibitor (ie, finasteride) was used as a positive control.
Th e weight of the rats was recorded on day a (ie, day I of th e study) and on day 14,
and the influence of testosteron e and test extracts on the weight of the rats was deter-
min ed. On day 14, rats were euthanized; prostates were dissected out, and weighed. The
rats' prostate/bod y weight (P/BW) rat io was then det erm ined . Hi stologic examinations
were performed on prostates from each group.
RESULTS: The petroleum ether extract as well as I3 hispida seed oil exhibited
inhibition of Sa-reductase activity in in vitro studies. Ethanolic extract did not
exhibit significant inhibirory potential in vitro. Further in vivo study found that
testosterone treatment significantly increased the rats ' P/BW ratio in all the groups
excep t the vehicle-treated rat s, and this increase in wcight was significantly inhib-
ited in rats administered petroleum ether extract (l00 and 200 mg /kg PO) and
B bispida seed oil (20 and 40 mg/kg PO). Ethanol ic extract did not exh ibit any
significant activity.
CONCLUSIONS: Petroleum ether extract and B bispida seed oil inhibited
testosterone-induced hyperplasia of the prostate in these rats. Further stu dies are
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needed to evaluate its effect in humans with benign prostatic hyperplasia. (Curr Ther
Res Gin Exp. 2010;71:331-343) © 2010 Elsevier HS Journals, Inc.
KEY WORDS: Benincasa hispida, Cucurbitaceae, benign prostatic hyperplasia,
prostate/body weight ratio, testosterone.
INTRODUCTION
Benign prostatic hyperplasia (BPH) is the result of gradual overgrowth of the prostate
gland, a gland that lies at the base of the bladder and encircles the urethra. J The en-
larged prostate impinges on the urethra and therefore BPH is generally associated
with impairment in urinary funcrion.f It is reported that 80% of men aged >80 years
suffer from BPH.3
Benincasa (Cucurbitaceae) is a monotypic genus with a single species, Benincasa
hispida Cogn. It is under cultivation in large areas in Indian states (ie, Uttar Pradesh,
Punjab, Rajasthan, Bihar). Traditionally, the fruit of B hispida is used as a diuretic and
the seeds have been reported to exhibit antiangiogenic effects on prostate cells."
B hispida seeds consist of steroids such as p-sitosterol and stigmast-5-ene-3-p-ol,
alkaloids such as 5-methy1cytosine, saponins, urea, citrulline, linoleic and oleic acids,
minute amounts of rriterpenoids known as isornultiflorenol and cucurbitacin B, and
proteins such as trigonelline, coffearin, and osmorin-"?
Cucurbita pepo (pumpkin) has been widely studied for its preventive actions
against BPH.8 Carbin er al? found that the actions of petroleum ether extract of the
pulp of C pepo fruits may be attributed to the content of phytosterols that are known
to interfere with the actions of dihydrotestosterone (DHT). Pumpkin seed oil has
been found to improve prostate health. In Budapest, Hungary, 60 patients with BPH
were treated with a prostate health supplement containing 300 mg of pumpkin
seed oil extract.!? Twenty-six patients administered the health supplement for
10 months, 22 patients for "27 months, and 12 patients for "24 months at a dosage
of 2 capsules 3 times daily in the first month and then 1 capsule 3 times daily. Based
on the results of urodynamic tests and the evaluation of changes in subjective
complaints, improvement was observed in >80% of the patients. There was an
increase in urinary flow while dysuric complaints, frequent and painful urination,
and frequency of nocturnal urination decreased. Being a member of the same fam-
ily and having a similar phytochemical profile," B bispid« might possess actions
similar to C pepo.
In the prostate, DHT is produced from testosterone by the enzyme 5a-reductase. J1
DHT is a potent androgen that promotes growth of the prostate. Although the patho-
genesis of BPH is not completely defined, these androgens have been identified as
playing an integral part in the disease process. Inhibition of the production or actions
of DHT can result in the inhibition of growth of the prostate gland. 12
There is substantial clinical evidence that androgens and DHT playa key role in
the development of BPH. \3Androgens are also involved in the development and pro-
gression of prostate cancer. Various approaches involving attenuation of androgenic
stimulation of prostatic growth and use of 5a-reductase inhibitors such as finasreride and
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epristeride have been employed, but their use has been limited by multiple adverse
effects (AEs).13 However, the magnitude of therapeutic effect produced by finasteride
is relatively small, and a clinically significant benefit is observed in less than half of
treated patients. Finasteride can cause AEs such as gynecomastia, impairment of
muscle growth, and severe myopathy, due to its structural similarity to steroidal hor-
mones. Therefore, it may be rewarding to look into traditional herbal medicines for
the management of BPH.
The present study was conducted to determine the antiandrogenic potential of
B hispida fruit on testosterone-induced hypertrophy in the prostate of rats. The in
vitro 5a-reductase inhibitory activity of the test extracts was first determined. In vivo
studies were then performed to validate the findings of the in vitro studies.
MATERIALS AND METHODS
PLANT MATERIAL
Fruits of B hispida were procured from local fields in Sagar (Madhya Pradesh, India).
The plant was authenticated by the Department of Botany, Dr. Harisingh Gour
University, Sagar, India. A herbarium has been deposited in the Department of Botany
and the accession number of the specimen is Bot/H/1994. Fruits were cut open with
a knife, seeds were separated from dried fruits manually, and the pulp was dried in the
sun to remove moisture. Seeds and dried pulp were coarsely powdered in a grinder.
PREPARATION OF EXTRACTS
Coarsely powdered pulp and seeds were fed in separate Soxhler extractors and extracted
with petroleum ether (60°C-80°C). The solvent from the petroleum ether extract was
eliminated under reduced pressure (yield: petroleum ether extract, 1.67% w/w; seed oil,
15.6% w/w). Then, the defatted marc of the pulp was extracted with alcohol (95% v/v) to
obtain the ethanolic extract (EE) (yield, 4.55% w/w).
DRUGS AND CHEMICALS
Testosterone was donated by Sun Pharma Advanced Research Center, Vadodara,
Gujarat, India. Finasteride was purchased from Sigma Aldrich, St. Louis, Missouri.
EDTA, sodium phosphate, and sucrose were purchased from Himedia Pvt. Ltd.,
Mumbai, India. Ethanol (95%) was purchased from Bengal Chemicals Pvt. Ltd., Kolkata,
India. Methanol, ethyl acetate, and petroleum ether (60°C-80°C) were purchased
from Qualigens Fine Chemicals Pvc. Ltd., Mumbai, India. All other chemicals used
in the study were of analytic grade.
IN VITRO STUDIES
With a view to explore the possibility that the extracts may have some action on
prostatic hyperplasia, the extracts were screened for 5a-reductase activity, the key
enzyme involved in hyperplasia of the prosrare.l ' The in vitro studies measured the
5a-reductase inhibitory potential of the extracts, seed oil, and finasteride by deter-
mining the concentration of testosterone in the reaction mixture using HPLC. 14 The
detailed methodology is described in the following sections.
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Preparation ofEnzyme Solution
Human prostate (about 200 mg) supplied from the local hospital of Sagar was
minced in small pieces and homogenized in 10 mL of medium A (20 mM sodium
phosphate, pH 6.5, containing 0.32 mM sucrose and 1 mM EDTA). The homogenate
was centrifuged at 4000 rpm (716g) for 15 minutes. The supernatant was used as a
source of enzyme. The concentration of enzyme in the supernatant was determined by
the Bradford method of protein estimation. l5
Preparation ofTest Materials
Testosterone (1 mM solution in ethanol) and extract/seed oil (1 mg/mL) were pre-
pared in ethanol (95%) with gentle heating wherever necessary. The EDTA solution
(l0 mg/mL) was made in distilled water. Finasteride (lO pg/rnl.) was prepared in
ethanol.
Determination ofOptimum Concentration ofEnzyme
Optimum enzyme concentration was determined by keeping the concentration of
substrate constant and varying the concentration of enzyme. Testosterone solution
(1 mM) was prepared in ethanol. The reaction mixture (l mL) was prepared by
combining testosterone solution (0.1 rnl.), enzyme solution (0.1-0.9 ml.), and sodium
phosphate buffer (20 mM). The reaction mixture was incubated at 37°C for 1 hour.
The reaction was terminated by the addition of 2 mL of ethyl acetate. The reaction
mixture was then shaken vigorously for 1 minute and the ethyl acetate layer was sepa-
rated. It was evaporated to dryness, and the residue dissolved in 2 mL of methanol.
Testosterone content in methanolic solution was estimated by HPLC (ATIO, Shirnadzu
Corp., Kyoto, Japan). The column was eluted isocratically with a mobile phase of
methanol:water (80:20) at a flow rate of 1.0 mL/min. 16 The optimum amount of
enzyme solution that converted testosterone to DHT was found to be 0.8 mL.
Determination ofInhibitory Concentrations ofExtract
The reaction mixture (1.5 mL) was made by adding 0.1 mL of testosterone solu-
tion, 0.1 mL of EDTA solution, 0.1 to 0.5 mL of extract/seed oil solutions depending
on the group, optimum amount of enzyme solution (ie, 0.8 rnl.), and sodium phos-
phate (20 mM), to a final volume of 1.5 mL. Reaction mixture was incubated at 3rC
for 60 minutes, and reaction was terminated by addition of 2 mL of ethyl acetate. The
mixture was vortexed for 1 minute; the ethyl acetate layer was separated and evapo-
rated to dryness. The residue was dissolved in methanol and made up to a volume of
2 mL with methanol. The residual testosterone content in methanol was determined
by HPLC. The column was eluted isocratically with a mobile phase of methanol.water
(80:20) at a flow rate of 1.0 mUmin. 16
IN VIVO STUDIES
The results of the in vitro studies were encouraging because appreciable 5a-
reductase inhibitory activity was found in the petroleum ether extract and seed oil of
B hispida. Along with petroleum ether extract and seed oil, EE was also included in
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the in vivo studies to assess its in vivo effects and to validate the findings of the in
vitro studies.
Animals
Male Sprague-Dawley rats weighing 115 to 125 g (aged 2-3 months) were housed
in polypropylene cages at room temperature (25 ± 2°C) and were fed a standard pellet
diet (Brooke Bond, Lipton, India) with water supplied ad libitum. The protocol for
animal experimentation was approved by the Institutional Animal Ethics Committee
of Dr. Harisingh Gour University.
Acute Toxicity Studies and Determination ofDoses
The petroleum ether extract, EE, and seed oil were subjected to acure toxicity stud-
ies to determine the dose for the in vivo studies according to the Organization for
Economic Cooperation and Development guidelines. 17 In all cases, a 2000-mg/kg oral
dose of the test extract was found to be tolerable, as no mortality was observed during
the study. On the basis of these studies, the doses of 100 and 200 mg/kg for petroleum
ether and EE were selected. These studies along with the previous studies on C pepo
seed oil determined the dose of seed oil for the present study. Using 1000 mg of seed
oil as the daily dose, rats were administered an oral dose of 2 or 4 mg/100 g (20-
40 mg/kg) once daily for 14 days.s
Preparation ofExtracts
Petroleum ether extract and EE were suspended in Tween-80 solution (2% v/v) for
oral administration. Rats were administered an oral dose of 100 and 200 mg/kg once
daily for 14 days. IS Seed oil was diluted with arachis oil to prepare the required dose.
Using 1000 mg of seed oil as the daily dose, tats were administered an oral dose of
2 or 4 mg/100 g (20-40 mg/kg) once daily for 14 days.f
Grouping and Treatment ofAnimals
Testosterone (3 mg/kg daily) dissolved in arachis oil was administered as a subcutane-
ous injection. IS The rats were placed in 9 groups of 10 rats each to receive test extracts,
testosterone, and Tween 80 (2% v/v) for the study period (ie, 14 days) as follows: group 1,
arachis oil (SC) + Tween 80 (2% v/v PO) (control); group 2, testosterone (SC) + Tween
80 (2% v/v PO); group 3, testosterone (SC) + petroleum ether extract (l00 mg/kg PO);
group 4, testosterone (SC) + petroleum ether extract (200 mg/kg PO); group 5, testoste-
rone (SC) + EE (l00 mg/kg PO); group 6, testosterone (SC) + EE (200 mg/kg PO);
group 7, testosterone (SC) + seed oil (20 mg/kg PO); group 8, testosterone (SC) + seed
oil (40 mg/kg PO); and group 9, testosterone (SC) + finasteride (1 mg/kg PO).
Body and Prostatic Weights
Weight was measured a day before treatment was started (baseline) and at 14 days of
treatment. On day 14, all animals were eurhanized under light ether anesthesia. The
prostates were immediately removed and weighed. Mean body weight and prostatic!
body weight ratios were calculated for each group.
335
CURRENT THERAPEUTIC RESEARCH
Histologic Studies
After prostatic weight measurements, the tissues were fixed in 10% formalin (in
normal saline). After 24 hours, the tissues were subjected to histologic studies using
microtome followed by hematoxylin and eosin staining. The slides were observed
under a microscope and the images recorded. The investigator who read the histology
specimens (A.N.) was blinded to the treatment groups.
STATISTICAL ANALYSIS
All results are expressed as mean (SO). Comparisons between groups were performed
with the Dunnett test using GraphPad Prism statistical software (GraphPad Software
Inc., La Jolla, California). P < 0.05 was considered to be statistically significant.
RESULTS
IN VITRO STUDIES
The optimum concentration of the enzyme was found to be 0.8 mL (270.0 rg protein
calculated by Bradford method of protein estirnationj.l? Varying concentrations of test
substances were incubated with a constant amount of testosterone and enzyme in reac-
tion mixture, and the residual testosterone content was determined after termination of
the reaction with ethyl acetate. The residual testosterone content in the reaction mixture
increased with increasing concentrations of petroleum ether extract, EE, and B hispida
seed oil. The inhibitory concentration of 50% (ICso) value was calculated by regression
analysis. The ICso calculated for petroleum ether extract, EE, seed oil, and finasteride
was 0.15 mg, 4.26 mg, 0.18 mg, and 1.06rg, respectively. Relative inhibitory potency
of the test material was, therefore, finasreride > petroleum ether extract> seed oil> EE
(Table I).
IN VIVO STUDIES
The results of the in vitro studies paved the way for the pharmacologic screen-
ing of the extracts to assess their potential against testosterone-induced hyperpla-
sia in rats.
Determination of Prostatic Weight and ProstatelBody Weight (P/BW) Ratio
In the group treated with testosterone alone, mean prostatic weight and P/BW ratio
were significantly increased after 14 days of injections compared with the control
group. The mean (SO) prostatic weights were 419.0 (11.5) mg and 253.5 (22.5) mg and
P/BW ratios were 2.70 (0.12) and 1.62 (0.11), respectively, for the testosterone-alone
group (P < 0.01 vs the testosterone + finasteride-treated group) and the control group
(P < 0.01 vs testosterone + finasteride-treated group).
Table II summarizes the effects of petroleum ether extract (100 and 200 mg/kg
PO), EE (100 and 200 mg/kg PO), seed oil (20 and 40 mg/kg PO), and finasteride
(l mg/kg PO) on prostatic hyperplasia induced with testosterone. In groups
treated with petroleum ether extract (100 mg/kg PO), the mean (SO) prostatic
weight and P/BW ratio were 338.0 (17.0) mg and 2.14 (0.06), respectively, and an
increase in dose (200 mg/kg PO) resulted in a mean prostatic weight of 334.3 (16.3) mg
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Table I. Sa-Reductase inhibitory concentrations (ICso) of
the treatment groups.
Group
Petroleum ether extract
Ethanolic extract
Benincasa hispida seed oil
Finasteride
0.15 mg
4.26 mg
0.18 mg
1.061Jg
and P/BW ratio of 2.12 (0.06). These observations were significant (P < 0.01)
compared with the group treated with testosterone alone, suggesting the efficacy of
petroleum ether extract and finasteride on testosterone-induced prostatic hyperplasia.
In the group treated with EE 100 mglkg PO, the mean prostatic weight and P/BW
ratio were 411.0 01.0) mg and 2.69 (0.01), respectively, and an increase in dose
(200 mg/kg PO) resulted in a mean prostatic weight of 421.002.4) mg and P/BW
ratio of 2.69 (0.01). These observations were 00( significant statistically compared
with the group treated with testosterone alone, whereas they were significant com-
pared with the group treated with finasteride. In groups treated with B hispida seed
oil 20 mglkg PO, the mean prostatic weight and P/BW ratio were 343.2 (4.8) mg
and 2.20 (0.04), respectively, and an increase in dose (40 mglkg PO) showed a
mean prostatic weight of 353.6 04.9) mg and P/BW ratio of 2.18 (0.04). These
observations were also significant (P < 0.01) compared with the group treated with
testosterone + finasteride, suggesting the efficacyon testosterone-induced prostatic hyper-
plasia. In the case of the finasteride-treared group, the mean (SD) prostatic weight was
325.805.7) mg and P/BW ratio was 2.04 (0.06). On the basis of mean prostatic weight
and P/BW ratios, we also calculated the percent recovery in P/BW ratio by test groups
compared with the group treated with testosterone alone. The increase induced by
testosterone alone was considered to be 100% and all other test groups were compared
with this reading, which was considered to be the control. The reduction in weight in-
duced by test materials was compared with the group treated with testosterone alone.
The formula used for calculation of percent recovery was as follows:
percent recovery by the test sample", A - B,
where A was the percent increase in prostatic weight induced by testosterone and B
was the percent increase in prosraric weight induced by the rest sample.
The percent recoveries thus calculated for the group treated with petroleum
ether extract at doses of 100 and 200 mglkg were 51.85% and 53.71%, respectively.
In rhe groups treated with EE, these recoveries were 0.93% and 0.92% for 100 and
200 mg/kg. Recovery with B hispida seed oil ar doses of 20 and 40 mglkg was 46.30%
and 48.15%, respectively. Recovery in the group treated with finasteride 0 mg/kg)
was 61.61 %.
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HISTOLOGIC EXAMINATIONS
Testosterone (3 mg/kg SC) + Tween 80 Group
In the group treated with testosterone alone, tubules appear to have become wider
compared with the control group (Figure, B and A, respectively). The walls of
tubules are thickened and almost every tubule developed large involutions projecting
into the lumen, reducing the volume of the lumen compared with the control group.
The amount of the secretion in some tubules was increased. The connective tissue
was compressed and blood vessels were dilated compared with the control. The
distinct nucleus and normal sarcoplasmic texture were not visible. There were some
connective tissue around the glands and papilla epithelial cells, and hematoxylin and
eosin-stained secretions were visible in some cavities. The shape of the tubules was
obliterated. Lumen was narrow, but at most places, the transitional nature of the
epithelium persisted.
Figure. Histologic examination of the effects of Benincasa hispida on testosterone-induced
prostatic hyperplasia in rats (100x magnification). (A) Control group (Tween 80
[2% v/v POl + arachis oil [3 mg/kg SCD; (8) testosterone alone (3 mg/kg SC);
(C) petroleum ether extract 100 mg/kg + testosterone (3 mg/kg SC); (D) petro-
leum ether extract 200 mg/kg + testosterone (3 mg/kg SC); (E) ethanolic
extract 200 mgjkg + testosterone (3 mg/kg SC); (F) B hispida seed oil 20 mgjkg +
testosterone (3 mg/kg SC); (G) B hispida seed oil 40 mg/kg + testosterone
(3 mg/kg SC); and (H) finasteride 1 mg/kg + testosterone (3 mg/kg SC).
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Testosterone + Petroleum Ether Extract (l00 and 200 mg/kg PO)
In the groups treated with petroleum ether extract (l00 or 200 mg/kg PO),
vacuolization in the cells appeared to be clear (Figure, C and D). The nucleus was
pyknotic (vacuole formation in outer layer of nucleus). Chromatin material in the
nucleus was normally distributed. The lumens of the tubules were normal, and in some
places the epithelium was slightly thicker than that of the control group. The lumens
were filled with more eosinophilic secretions. Squamous cells were sparse in number,
but more cuboidal and pear-shaped cells were present in the transitional epithelium.
Involutions were few in number and even less than whar were observed in the control
group. Connective tissue between the tubules was reduced. Tubules appear to have large
lumen. The stroma didn't exhibit any analogy to the cells in the control group.
Testosterone + EE (100 or 200 mg/kg PO)
Both groups treated with EE appeared to be similar to the group rreated with tes-
tosterone alone (Figure, E). No improvement in volume of the lumen, sarcoplasmic
texture, or stromal distribution was visible in this group, except in the shape and size
of the tubules compared with the testosterone-treated group. The epithelium was
more maintained compared with the group treated with testosterone alone.
Testosterone + B Hispida Seed Oil (20 or 40 mg/kg PO)
In the groups treated with B hispida seed oil (20 or 40 mg/kg PO), better intralu-
minal secretions appeared and tubules had morphologic improvement in the texture
(Figure, F and G). The epithelium was still wider and thicker. Compared with the
group treated with testosterone alone, the stroma (composed of connective and smooth
muscle cells) appeared normal. End secretory parts of the gland were more maintained
than those in the testosterone-alone and petroleum ether extract groups. The appear-
ance of the transitional epithelium resembled that of the control group. The involu-
tions were thicker than those observed in the control group. However, some tubules
had wider lumens with smooth transitional epithelium. Minor curvature in the epi-
thelium was also observed. Involutions in the epithelium were fewer and thicker than
that of the control group.
Testosterone + Finasteride (l mg/kg PO)
With normal distribution of stroma, this group had a texture similar to that observed
in the B hispida seed oil group. The projections were not as prominent as observed in the
group treated with testosterone alone. Although finasreride appeared to antagonize the
effects of testosterone to a certain degree, several cells with increased volume were observed
throughout the transitional epithelium. Cells with swollen nuclei were prominent in many
places. Reduced involutions in lesser number were observed (Figure, H).
Control Group (Arachis Oil)
Normal histologic features of prostate gland are visible, showing the tubules of vari-
able diameter and irregular lumen (Figure, A). The lumens were filled with prostatic
secretions. In connective tissue, blood vessels, and lymph vessels, the matrix was nor-
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mal. In some places, aggregation of columnar cells was observed. The prostate gland
was surrounded by a capsule; a thick layer of involuntary muscles with a distinct
nucleus and normal sarcoplasmic texture was visible. Some pyramidal cells were also
observed in the intermediate layers.
DISCUSSION
Testosterone is converted to more potent DHT by the enzyme 5a-reductase type 2
present in prostate homogenares.U'V With the addition of petroleum ether extract,
EE, and B hispida seed oil in reaction mixtures, increased levels of unchanged testos-
terone were found in the reaction mixture, suggesting inhibition of enzyme action by
these test materials. Furthermore, the inhibition of conversion by these materials
clearly reflects that activity is blocked, and therefore more testosterone remains un-
changed in the reaction mixture.
The results of the present investigation suggest that petroleum ether extract and
B hispida seed oil at different dose levels inhibited prostatic hyperplasia induced with
an exogenous supply of testosterone in a rat model. In the group treated with testos-
terone alone, subcutaneous injection of testosterone increased prostatic weight and P/BW
ratio compared with the control group (vehicle only).
The effects of testosterone and DHT on prostatic growth in rodents have previously
been documented and used to assess the effects of drugs used for the treatment of pros-
tatic hyperplasia, including saw palmetto fruit lipid extract.23,24 The results presented
here suggest that petroleum ether extract and B hispida seed oil were associated with the
significant attenuation of prostatic hyperplasia in rats. The in vitro studies identified the
mechanism of prevention of prostatic hyperplasia induced by testosterone. It is evident
that petroleum ether extract and B hispida seed oil have 5a-reductase-inhibitory
activity. The histologic findings of recovery in the tubular latency and shape further
support B hispida as a strong investigational candidate for the management of pros-
tatic hyperplasia. Further studies are necessary to confirm the effect of the drug on
BPH in humans.
LIMITATIONS
The etiology of BPH in humans is heterogeneous, and no other species shows the
same complexity of this disorder. Animal models of BPH studied to date do not ap-
pear to fully mimic the stromal and epithelial changes with BPH in humans. 19 There-
fore, in vitro and experimental models are of limited value for the study of BPH events
in humans. Spontaneous animal models are limited to nonhuman primates and canines
(hormone-induced BPH in canines appears to be an especially replicate model of hu-
man BPH), bur ethical and economic problems have reduced the applicability of these
models.I" In particular, BPH induced with testosterone or DHT does not reproduce
all findings of BPH in humans because the pathogenesis of BPH is dependent on a
functional androgenic signal involving several components (eg, testosterone synthesis
in the testes, conversion of testosterone to DHT, transportation of DHT to target
prostate tissues, binding of DHT to androgenic receptor and the subsequent gene
modulation).20-22 BPH in humans also involves prostatic estrogens and a-adrenergic
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receptors not fully reproducible in other models. Thus, the model used in the present
study has limitations in predicting the effects of any treatment in the management of
BPH in humans. A further limitation of this study was the lack of an objective scoring
system for the histologic examinations; however, there is presently no gold standard
scoring system for prostate histology.
CONCLUSION
The results of the present investigation suggest that petroleum ether extract and
B hispida seed oil at different dose levels inhibited prostatic hyperplasia induced by an
exogenous supply of testosterone in a rat model.
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